Lucy Rutten: An Important Mechanistic Insight Into Future Vaccine Safety
Lucy Rutten, Senior Scientist at Leiden University, shared on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Proud to share our recent publication in The New England Journal of Medicine.
This international collaboration began in the early phase of investigating rare cases of vaccine-induced immune thrombocytopenia and thrombosis (VITT) following adenoviral vector–based COVID-19 vaccination.
In this study, we elucidate how antibodies initially directed against adenoviral core protein VII can, in rare instances, cross-react with platelet factor 4 (PF4), a key clotting factor, due to a specific somatic mutation (K31E) in the antibody.
These findings provide important mechanistic insight into pathogenesis and future vaccine safety.
It has been a privilege to contribute to this long-standing and highly collaborative effort.”
Title: Adenoviral Inciting Antigen and Somatic Hypermutation in VITT
Authors: Jing Jing Wang, Linda Schönborn, Theodore E. Warkentin, Luisa Müller, Thomas Thiele, Lena Ulm, Uwe Völker, Sabine Ameling, Sören Franzenburg, Lars Kaderali, Ana Tzvetkova, Alex Colella, Tim Chataway, Chee Wee Tan, Bridie Armour, Alexander Troelnikov, Lucy Rutten, James McCluskey, Roland Zahn, Tom P. Gordon, Andreas Greinacher
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 8, 2026, 11:33Ifeanyichukwu Ifechidere: Haemophilia A and B – From First Diagnosis to the Era of Gene Therapy
-
Jul 8, 2026, 10:29Bringing Hemophilia Care Closer to Communities in Togo – WFH
-
Jul 8, 2026, 10:12Natasha Jolakoski: Completing Advanced Training in Thrombosis and Hemostasis
-
Jul 8, 2026, 09:58Rola Ghasoub: Early Intracranial Hemorrhage Remains the Main Barrier to Cure in Acute Promyelocytic Leukemia
-
Jul 8, 2026, 05:53Excellent PhD Defense by Roberta Cirsmaru on Gene Therapy for Hemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Jul 8, 2026, 05:48Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
-
Jul 8, 2026, 05:39Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis
-
Jul 8, 2026, 04:50Reza Bavarsad Shahripour: New AHA Guidance on Cryptogenic Stroke with Reduced Left Ventricular Function
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism